9/20/2023

Rocuronium Injection

Products Affected - Description

- Rocuronium Bromide solution for injection, Baxter, 10 mg/mL, 10 mL vial, 10 count, NDC 43066-0013-10
- Rocuronium Bromide solution for injection, Fresenius Kabi, 10 mg/mL, 10 mL vial, 10 count, NDC 63323-0426-10
- Rocuronium Bromide solution for injection, Hikma, 10 mg/mL, 10 mL vial, 10 count, NDC 00143-9251-10
- Rocuronium Bromide solution for injection, Hikma, 10 mg/mL, 5 mL vial, 10 count, NDC 00143-9250-10
- Rocuronium Bromide solution for injection, Pfizer, 10 mg/mL, 10 mL vial, 10 count, NDC 00409-9558-10
- Rocuronium Bromide solution for injection, Sagent, 10 mg/mL, 10 mL vial, 10 count, NDC 25021-0662-10
- Rocuronium Bromide solution for injection, Sagent, 10 mg/mL, 5 mL vial, 10 count, NDC 25021-0662-05

Reason for the Shortage

- Athenex is no longer marketing rocuronium.
- Baxter has rocuronium injection on shortage due to increased demand.
- Eugia has rocuronium injection available.
- Fresenius Kabi has rocuronium injection on shortage due to increased demand.
- Hikma has rocuronium injection on shortage due to increased demand.
- Pfizer has rocuronium on shortage due to manufacturing delays.
- Piramal Critical Care did not provide a reason for the shortage.
- Sagent did not provide a reason for the shortage.
- Sandoz did not provide a reason for the shortage.
- Viatris did not provide a reason for the shortage.
- X-Gen has rocuronium injection on shortage due to increased demand.

Available Products

- Rocuronium Bromide solution for injection, Baxter, 10 mg/mL, 5 mL vial, 10 count, NDC 43066-0007-10
- Rocuronium Bromide solution for injection, Eugia US, 10 mg/mL, 10 mL vial, 10 count, NDC 55150-0226-10
- Rocuronium Bromide solution for injection, Eugia US, 10 mg/mL, 5 mL vial, 10 count, NDC 55150-0225-05
- Rocuronium Bromide solution for injection, Fresenius Kabi, 10 mg/mL, 5 mL vial, 10 count, NDC 63323-0426-05
- Rocuronium Bromide solution for injection, Mylan Institutional (Viatris), 10 mg/mL, 10 mL vial, 10 count, NDC 67457-0228-10
- Rocuronium Bromide solution for injection, Mylan Institutional (Viatris), 10 mg/mL, 5 mL vial, 10 count, NDC 67457-0228-05
- Rocuronium Bromide solution for injection, Pfizer, 10 mg/mL, 10 mL vial, 10 count, NDC 00409-7037-10
- Rocuronium Bromide solution for injection, Pfizer, 10 mg/mL, 5 mL vial, 10 count, NDC 00409-3189-10
- Rocuronium Bromide solution for injection, Piramal Critical Care, 10 mg/mL, 10 mL vial, 10 count, NDC 66794-0229-41
- Rocuronium Bromide solution for injection, Piramal Critical Care, 10 mg/mL, 5 mL vial, 10 count, NDC 66794-0228-41
- Rocuronium Bromide solution for injection, Sandoz, 10 mg/mL, 10 mL vial, 10 count, NDC 00781-3220-92
- Rocuronium Bromide solution for injection, Sandoz, 10 mg/mL, 5 mL vial, 10 count, NDC 00781-3220-95
- Rocuronium Bromide solution for injection, X-Gen, 10 mg/mL, 10 mL vial, 10 count, NDC 39822-4200-06
- Rocuronium Bromide solution for injection, X-Gen, 10 mg/mL, 5 mL vial, 10 count, NDC 39822-4200-02

Estimated Resupply Dates

- Baxter has rocuronium 10 mg/mL 10 mL vials available in limited supply.
- Fresenius Kabi has rocuronium 10 mg/mL 10 mL vials on back order and the company estimates a release date of late-September 2023.
- Hikma has rocuronium 10 mg/mL 5 mL and 10 mL vials on back order and the company estimates a release date of early-October 2023.
- Sagent has rocuronium 10 mg/mL 5 mL vials on back order and the company estimates a release date of October 2023. The 10 mL vials are on back order and the company cannot estimate a release date.

Updated

Updated September 20, 2023 by Leslie Jensen, PharmD, Drug Information Specialist. Created February 9, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.